Skip to main content
SpringerLink
Log in

Aspirin use in elderly women receiving medication therapy management services

  • Original Research
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

Cardiovascular disease is the largest single cause of death among women in the US. The American Heart Association guidelines recommend aspirin use in women ≥65 years of age if blood pressure is controlled and the benefits of cardiovascular risk reduction likely outweigh the risk of bleeding. The objective of this study is to determine the prevalence of aspirin use in elderly women and factors associated with use.

Methods

This retrospective study evaluated aspirin use in women aged ≥65 years based on cardiovascular and gastrointestinal bleeding risk using a medication therapy management database within a large mid-Atlantic managed care organization. Logistic regression was used to analyze patient-related variables associated with aspirin use. Variables included clinical coronary heart disease (CHD), number of CHD risk factors, diabetes diagnosis, number of chronic medications and presence of contraindications to aspirin.

Results

Aspirin use was reported in 50% of patients: 68.0% in the secondary prevention group and 46.3% in the primary prevention group. The percentage of patients using aspirin or with relative aspirin contraindications increased to 84% for the secondary prevention group and 65.9% for the primary prevention group. Patients with clinical CHD and those with diabetes and without clinical CHD were 5.88 (P=0.008) and 7.54 (P=0.012) times more likely to utilize aspirin, respectively, than patients with only one CHD risk factor of age. Patients with relative contraindications to aspirin were less likely to use aspirin (P<0.001).

Conclusion

The high use of aspirin in patients at higher CHD risk supports national recommendations. Clinical practitioners need to carefully assess the value of aspirin in patients at low CHD risk and those 80 years of age and beyond where evidence of benefit should be weighed against risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Heart Association. Heart Disease and Stroke Statistics: 2010 Update At-A-Glance. Dallas, Texas: American Heart Association; 2010. c2010, American Heart Association. Available at: www.americanheart.org/downloadable/heart/1265665152970DS-3241%20HeartStrokeUpdate_2010.pdf. Accessed June 1, 2010.

    Google Scholar 

  2. Antithrombotic Trialists’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71–86.

    Article  Google Scholar 

  3. US Preventive Services Task Force. Aspirin for the prevention of cardiovascular disease: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2009;150:396–404.

    Google Scholar 

  4. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevent ion of cardiovascular disease in women. N Engl J Med. 2005;352:1293–1304.

    Article  CAS  PubMed  Google Scholar 

  5. Chan AT, Manson JE, Feskanich D, Stampfer MJ, Colditz GA, Fuchs CS. Long-term aspirin use and mortality in women. Arch Intern Med. 2007;167:562–572.

    Article  PubMed  Google Scholar 

  6. Mosca L, Banka, CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. Circulation. 2007;115:1451–1501.

    Article  Google Scholar 

  7. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533–543.

    CAS  PubMed  Google Scholar 

  8. Pignone M, Anderson GK, Binns K, Tilson HH, Weisman SM. Aspirin use among adults aged 40 and older in the United States: results of a national survey. Am J Prev Med. 2007;32:403–407.

    Article  PubMed  Google Scholar 

  9. Berger JS, Brown DL, Burke GL, et al. Aspirin use, dose, and clinical outcomes in postmenopausal women with stable cardiovascular disease. Circ Cardiovasc Qual Outcomes. 2009;2:78–87.

    Article  PubMed  Google Scholar 

  10. Cho L, Hoogwerf B, Huang J, Brennan DM, Hazen SL. Gender differences in utilization of effective cardiovascular secondary prevention: a Cleveland clinic prevention database study. J Womens Health (Larchmt). 2008;17:515–521.

    Article  Google Scholar 

  11. Ajani UA, Ford ES, Greenland KJ, Giles WH, Mokdad AH. Aspirin use among U.S. adults: Behavioral Risk Factor Surveillance System. Am J Prev Med. 2006;30:74–77.

    Article  PubMed  Google Scholar 

  12. Stafford RS, Monti V, Ma J. Underutilization of aspirin persists in US ambulatory care for the secondary and primary prevention of cardiovascular disease. PLoS Med. 2005;2:e353. Epub 2005 Nov 15.

    Article  PubMed  Google Scholar 

  13. American Diabetes Association. Standards of medical care in diabetes — 2007. Diabetes Care. 2007;30(suppl. 1):S4–41.

    Article  Google Scholar 

  14. American Diabetes Association. Standards of medical care in diabetes — 2009. Diabetes Care. 2009;32(suppl. 1):S13–S61.

    Article  Google Scholar 

  15. Laine L. Review article: gastrointestinal bleeding with low-dose aspirin — what’s the risk? Aliment Pharmacol Ther. 2006;24:897–908.

    Article  CAS  PubMed  Google Scholar 

  16. Antithrombotic Trialists’ (ATT) Collaboration. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet. 2009;373:1849–1860.

    Article  Google Scholar 

  17. Lip GYH, Felmeden DC. Antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev. 2008;(4):CD003186.

  18. Redberg RF, Benjamin EJ, Bittner V, et al. ACCF/AHA 2009 Performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Performance Measures (Writing committee to develop performance measures for primary prevention of cardiovascular disease): developed in collaboration with the American Academy of Family Physicians; American Association of cardiovascular and Pulmonary Rehabilitation; and Preventive Cardiovascular Nurses Association; endorsed by the American College of Preventive Medicine, American college of Sports Medicine, and Society for Women’s health Research. Circulation 2009;120:1296–1336.

    Article  PubMed  Google Scholar 

  19. Wolff T, Miller T, Ko S. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2009;150:405–410.

    PubMed  Google Scholar 

  20. De Berardis G, Sacco M, Strippoli GF, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531.

    Article  PubMed  Google Scholar 

  21. Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295:306–313.

    Article  CAS  PubMed  Google Scholar 

  22. Persell SD, Zei C, Cameron KA, Zielinski M, Lloyd-Jones DM. Potential use of 10-year and lifetime coronary risk information for preventive cardiology prescribing decision: a primary care physician survey. Arch Intern Med. 2010;170:470–477.

    Article  PubMed  Google Scholar 

  23. Romero SC, Dela Rosa KM, Linz PE. Aspirin for primary prevention of coronary heart disease: using the Framingham Risk Score to improve utilization in a primary care clinic. South Med J. 2008;101:725–729.

    PubMed  Google Scholar 

  24. Rodondi N, Vittinghoff E, Cornuz J, et al. Aspirin use for the primary prevention of coronary heart disease in older adults. Am J Med. 2005;118:1288

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CareFirst BlueCross BlueShield, Baltimore, MD, USA

    Helen Y. Lee

  2. Denver VA Medical Center, Denver, CO, USA

    Yvette P. Tong

  3. University of Maryland School of Pharmacy, Baltimore, MD, USA

    Shan Xing

  4. PosiHealth, Inc., 5106 Bonnie Branch Road, Ellicott City, MD, 21043, USA

    Catherine E. Cooke

  5. University of Maryland School of Pharmacy, Baltimore, MD, USA

    Catherine E. Cooke

Authors
  1. Helen Y. Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yvette P. Tong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Shan Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Catherine E. Cooke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Catherine E. Cooke.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lee, H.Y., Tong, Y.P., Xing, S. et al. Aspirin use in elderly women receiving medication therapy management services. Adv Therapy 27, 613–622 (2010). https://doi.org/10.1007/s12325-010-0046-1

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-010-0046-1

Keywords

Search

Navigation